Tranexamic acid for bleeding in the brain from a stroke

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who have had a sudden bleed inside the brain (intracerebral haemorrhage) in the last 4.5 hours and are given tranexamic acid (TXA).

Age

18 years or older

Sex

All sexes can join

Disease stage

Spontaneous bleed in the brain, confirmed on a brain scan, within 4.5 hours of onset. If the start time is unknown, within 4.5 hours of when the symptoms were discovered.

Earlier treatment

People taking direct oral anticoagulants can join. People taking warfarin or low molecular weight heparin at the time of enrolment cannot join.

Main reasons for not taking part

• Known reason to be treated with TXA, for example traumatic brain injury
• Active seizures, or a current blood clot in a vein or artery
• Known allergy to TXA or normal saline
• Known problem in the brain's structure, such as aneurysm, tumor or arteriovenous malformation
• Very large bleed (more than 60ml), severe coma (Glasgow Coma Scale below 5), or end-of-life care already decided

What the trial wants to find out

To assess the clinical effectiveness of TXA after ICH and determine whether TXA should be used in clinical practice. Primary objective: To assess the effect of TXA on early death (≤28days)